Maravai LifeSciences Quarterly Cash Flow Statement
NASDAQ: MRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maravai LifeSciences free cash flow
In the quarter ended Jun 30, 2026, Maravai LifeSciences generated $4.0 million of operating cash flow and spent $370,000 on capital expenditures. That left free cash flow of $3.6 million, a free-cash-flow margin of 7.0% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Maravai LifeSciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -21.63M | -6.38M | -63.02M | -45.06M | -69.84M | -52.85M | -46.07M | -172.46M | -18.42M | -22.68M | -109.98M | -15.10M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | -225.80% | -115.15% |
| Depreciation & Amortization | 5.31M | 4.90M | 5.93M | 5.97M | 5.96M | 5.69M | 5.47M | 5.04M | 5.56M | 4.79M | 3.93M | 4.07M |
| Stock-Based Compensation | 10.21M | 6.74M | 3.93M | 9.06M | 6.79M | 10.40M | 10.54M | 13.05M | 13.76M | 12.06M | 9.34M | 9.99M |
| Change in Working Capital | 764.00K | -5.62M | -17.72M | 6.88M | 6.21M | 14.36M | -8.97M | 1.14M | 9.89M | -9.52M | 3.41M | 9.66M |
| Operating Cash Flow | 3.99M | 8.66M | -22.77M | -15.15M | -10.27M | -9.39M | -14.64M | 13.14M | 17.43M | -8.47M | 7.79M | 14.17M |
| Capital Expenditures | -370.00K | -4.44M | -2.11M | -3.66M | -2.87M | -4.50M | -5.85M | -8.59M | -9.55M | -5.67M | -16.80M | -15.83M |
| Investing Cash Flow | -370.00K | -4.44M | -2.11M | -2.93M | -3.24M | -23.13M | -4.93M | -8.96M | -6.18M | -4.24M | -12.90M | -15.52M |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Debt Repaid | -242.88M | -51.36M | -1.36M | -1.36M | -1.36M | -1.36M | -230.31M | -1.36M | -1.36M | -1.36M | -1.36M | -1.36M |
| Financing Cash Flow | -98.98M | -55.23M | -1.82M | -8.25M | -1.53M | -4.90M | -236.19M | 809.00K | 228.00K | -560.00K | 470.00K | 783.00K |
| Net Change in Cash | -95.34M | -50.97M | -26.68M | -26.33M | -15.15M | -37.35M | -255.76M | 4.99M | 11.48M | -13.27M | -4.64M | -571.00K |
| Free Cash Flow | 3.62M | 4.23M | -24.88M | -18.81M | -13.14M | -13.89M | -20.49M | 4.54M | 7.88M | -14.13M | -9.01M | -1.66M |
This table shows 12 quarterly periods of Maravai LifeSciences's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MRVI's reporting calendar. What is a cash flow statement?